The Patients’ Voice in the Evaluation of Orphan Drugs
Abstract
This article considers ways that health technology assessment bodies can take into account the voice of patients with rare diseases when granting access to orphan drugs.
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now